Healthcare

Greenwich LifeSciences interview scheduled for RedChip programme on Bloomberg TV and CNBC

Greenwich LifeSciences CEO Snehal Patel is scheduled to discuss GLSI-100, clinical development and manufacturing progress during a RedChip television interview airing on Bloomberg TV and CNBC.

Published:
Reading Time
3 min

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel is scheduled to appear on RedChip Companies’ sponsored Small Stocks, Big Money™ programme, with broadcasts planned on Bloomberg TV and CNBC. The interview will cover the company’s GLSI-100 immunotherapy, the Phase III FLAMINGO-01 trial, clinical expansion and manufacturing activities.

#Broadcast schedule

The interview is scheduled for Bloomberg TV on Saturday, November 14, at 7:00 p.m. Eastern Time (ET). CNBC is scheduled to air the programme on Sunday, November 15, at 11:30 a.m. ET.

RedChip states that Bloomberg TV is available in an estimated 73 million homes across the United States, while CNBC is available in approximately 90 million U.S. households.

#GLSI-100 development programme

Greenwich LifeSciences is developing GLSI-100 as an immunotherapy intended to help prevent the return of HER2-positive breast cancer after surgery and standard antibody treatment. The treatment combines the GP2 peptide with GM-CSF to stimulate an immune response against recurring cancer cells.

The company said a Phase IIb clinical trial showed an approximately 80% reduction in breast cancer recurrence. It said the result supports the treatment’s potential to address an unmet medical need and reduce the risk of metastatic disease.

#Early Phase III findings

Patel is expected to discuss early results from the ongoing Phase III FLAMINGO-01 trial. Greenwich LifeSciences reported strong immune responses and preliminary recurrence trends among patients regardless of HLA type.

The open-label, non-HLA-A02 cohort has shown an approximately 80% reduction in recurrence based on the company’s preliminary observations. Greenwich said the finding is consistent with the earlier Phase IIb result, while also stating that the observations remain early and require further validation.

According to the company, broader eligibility beyond the initially targeted HLA-A02 group could potentially increase its annual target population from approximately 44,000 to 88,000 patients across the United States and Europe. This is an estimate from Greenwich LifeSciences and is subject to the development of the programme.

#Trial network and manufacturing

Greenwich LifeSciences said it has approximately 160 clinical sites across the United States and Europe. The company is continuing patient enrolment and pursuing protocol modifications intended to expand eligibility and strengthen its planned interim analyses.

The company also said a potential expansion to approximately 200 trial sites is under consideration, with additional clinical data presentations and interim analyses anticipated. These activities remain part of the ongoing clinical development programme.

On manufacturing, Greenwich LifeSciences said the FDA is reviewing manufacturing data and that commercially manufactured GLSI-100 clinical supplies are being used in the U.S. Phase III trial.

#Company and RedChip relationship

Greenwich LifeSciences describes itself as a clinical-stage biopharmaceutical company focused on GP2-based immunotherapy for preventing breast cancer recurrence in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein. The company states that HER2 is expressed in 75% of breast cancers at low, intermediate and high levels.

RedChip Companies provides investor relations and media services to Greenwich LifeSciences and receives compensation for those services. RedChip also states that it does not independently verify all information contained in the announcement and makes no representation or warranty regarding its accuracy or completeness.

#Key Takeaways

  • Greenwich LifeSciences CEO Snehal Patel is scheduled to appear on RedChip’s sponsored programme.
  • The interview is scheduled for Bloomberg TV on Saturday, November 14, at 7:00 p.m. ET and CNBC on Sunday, November 15, at 11:30 a.m. ET.
  • Greenwich reported an approximately 80% reduction in recurrence in its Phase IIb trial and in preliminary observations from its open-label, non-HLA-A02 cohort.
  • The company said its Phase III FLAMINGO-01 findings are early and require further validation.
  • Greenwich reported approximately 160 clinical sites, FDA review of manufacturing data and the use of commercially manufactured GLSI-100 supplies in the U.S. Phase III trial.

Original source: Read original article

Frequently Asked Questions